<DOC>
	<DOCNO>NCT02173080</DOCNO>
	<brief_summary>This Pilot study enable development &amp; assessment Polycystic Liver Disease-specific patient report outcome questionnaire ( PLD-Q ) . Polycystic liver disease ( PLD ) characterize formation numerous cyst liver , lead severe symptomatic hepatomegaly . It common patient autosomal dominant polycystic liver disease ( ADPLD ) autosomal dominant polycystic kidney disease ( ADPKD ) .</brief_summary>
	<brief_title>Development Assessment The Polycystic Liver Disease Questionnaire ( PLD-Q ) .</brief_title>
	<detailed_description>As liver function preserve , quality life main outcome PLD . Patient report outcomes increasingly utilized ass treatment efficacy &amp; include endpoint derive patient report &amp; usually assessed questionnaire . Several exist generic questionnaire assess gastrointestinal symptom , include irrelevant item polycystic liver disease ( PLD ) &amp; examine relevant extra-abdominal symptom . Also , questionnaire ass full range PLD relate problem likely responsive change treatment initiation . Therefore , tool accurately detect change PLD symptom require . The development first step validation questionnaire already complete Netherlands . We develop questionnaire English speaking patient validate Mayo Clinic cohort . The study contain three phase . Phase 1 : pilot test directly translate questionnaire ( dutch english ) small group polycystic liver disease ( PLD ) patient . We include symptomatic &amp; asymptomatic patient ( i.e . mild severe PLD ) . Phase 2 : refinement questionnaire use result pilot test input Mayo patient clinician focus group . Phase 3 : Further validation large cohort 200 PLD patient ( 1 ) comparison 200 control without PLD , ( 2 ) cross-sectional correlation total liver ( TLV ) &amp; kidney volume ( TKV ) , ( 3 ) compare ADPKD patient &amp; without PLD ( 5 ) validate questionnaire ( e.g . SF36 ) &amp; ( 5 ) development custom `` Worry Questionnaire '' examine disease-related worry &amp; concern . Finally , longitudinal analysis perform assess PLD-Q sensitivity change symptom . Statistical &amp; psychometric analysis provide Mayo Clinic quality life Research group , &amp; develop accordance Food Drug Administration ( FDA ) guidance patient-reported outcome measure consultation Study Endpoints &amp; Labeling Development Division .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cysts</mesh_term>
	<criteria>Patients â‰¥ 18 year Polycystic liver , define &gt; 20 liver cyst image Patients unable speak read English properly History kidney liver transplantation Dialysis Current use experimental drug ( e.g . lanreotide , octreotide ) Recent liver resection major surgery Other comorbidities affect outcome questionnaire , deem investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>autosomal dominant polycystic liver disease</keyword>
	<keyword>autosomal dominant polycystic kidney disease</keyword>
	<keyword>quality life</keyword>
	<keyword>patient report outcome tool</keyword>
</DOC>